公开(公告)号：US11413270B2

公开(公告)日：2022-08-16

申请号：US16908195

申请日：2020-06-22

Applicant: NOVMETAPHARMA CO., LTD.

Inventor： Heon Jong Lee ,  Hoe Yune Jung ,  In-Kyu Lee ,  Jae-Han Jeon ,  Sung Jin Cho

IPC: A61K31/397 ,  A61K31/495 ,  A61K31/4453 ,  A61K31/5375 ,  A61K31/4025 ,  A61P1/18 ,  A61K31/454 ,  A61K31/407 ,  A61K31/4525 ,  A61K31/403 ,  A61K31/4192 ,  A61K31/396

Abstract: A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

公开(公告)号：US20220362269A1

公开(公告)日：2022-11-17

申请号：US17852774

申请日：2022-06-29

Applicant: NovMetaPharma Co., Ltd.

Inventor： Heon Jong LEE ,  Heo Yune Jung ,  In-Kyu Lee ,  Jae-Han Jeon ,  Sung Jin Cho ,  Jina Kim ,  Hayoung Hwang ,  Yong Hyun Jeon ,  Jungwook Chin

IPC: A61K31/695 ,  A61K31/495 ,  A61K31/4453 ,  A61K31/5375 ,  A61K31/40 ,  A61K31/396 ,  A61K31/397 ,  A61K31/454 ,  A61K31/4025 ,  A61K31/407 ,  A61K31/443 ,  A61K31/403 ,  A61K31/433 ,  A61P1/18

Abstract: A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. Also disclosed is a use of the aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, in manufacturing a medicament for preventing and/or treating pancreatitis or for treating one or more symptoms of pancreatitis in a patient. The method of prevention and/or treatment of pancreatitis includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

公开(公告)号：US20230390279A1

公开(公告)日：2023-12-07

申请号：US18204520

申请日：2023-06-01

Applicant: NOVMETAPHARMA CO., LTD.

Inventor： Keun Gyu Park ,  In Kyu Lee ,  Sung Jin Cho ,  Yeon Kyung Choi ,  Mi Jin Kim ,  Jung Wook Chin ,  Yong Hyun Jeon ,  Jin A Kim ,  Dong Su Kim ,  Hoe Yune Jung ,  Do Hyun Lee

IPC: A61K31/495 ,  A61K39/395 ,  A61P35/00 ,  A61K31/7105 ,  A61K31/451 ,  A61K31/5377 ,  A61K31/47 ,  A61K31/506 ,  A61K31/519

CPC classification number: A61K31/495 ,  A61K39/3955 ,  A61P35/00 ,  A61K31/7105 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/47 ,  A61K31/506 ,  A61K31/451

Abstract: A new use of estrogen-related receptor γ (ERRγ) inhibitor in enhancing cancer treatment and a pharmaceutical composition for inhibiting the resistance of cancer to tyrosine kinase inhibitors and enhancing an anticancer effect are disclosed. The pharmaceutical composition contains an ERRγ inhibitor as an active ingredient. The pharmaceutical composition for treating tyrosine kinase inhibitor-resistant advanced cancer. The composition can be administered in combination with tyrosine kinase inhibitor. A method for determining if a cancer is tyrosine kinase-resistant is also disclosed.